ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China
June 15, 2021ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in both China and the U.S. on May 28 2021 and June 11 2021 ... -
BMS signs $475m licensing deal with Dragonfly Therapeutics
August 19, 2020Bristol Myers Squibb (BMS) has signed an agreement for an exclusive worldwide licence to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy programme.
Pharma Sources Insight January 2025
